The latest multi-cohort meta-analyses and case-control studies indicate that IGF-I can not only distinguish prostate cancer patients from those with benign prostatic hyperplasia and normal individuals, but also further distinguish high Gleason grade (aggressive) tumors from indolent tumors (2, 15). The gene discussed is IGF1; the disease is prostate carcinoma.